SYNERGIC COMPOSITION BETWEEN BETA-LAPACHONA AND ANTIMICROBIANS AGAINST MULTIRESITENT ENTEROCOCCUS FAECALIS

摘要

The present invention comprises the use of a composition with antimicrobial activity as an alternative to the treatment of multiresistant enterococcus faecalis infections whose results have been found to be synergistic between beta-lapachone / vancomycin, beta-lapachone / gentamicin; beta-lapachone / ampicillin; and beta-lapachone / ciprofloxacin. an additive effect was obtained for the beta-lapachone / ciprofloxacin combination on growth inhibition of enterococcus faecalis lfbm 671 and 272 strains. these combinations showed potentiated anti-enterococcal activity, reversing the resistance of enterococcus faecalis strains to all antimicrobials used. , reducing the minimum inhibitory concentration cim from 75% to 96.88% of antimicrobials and from 75% to 98.4% for beta-lapachone. This reduction in the minimum inhibitory concentration will also induce reductions in costs and adverse effects. This composition may be applied to human and veterinary health. mainly in pharmaceutical, dental and related products.